Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Core Points - Verona Pharma is a biopharmaceutical company focused on developing therapies for chronic respiratory diseases with significant unmet medical needs [1] - The company's first commercial product, OhtuvayreTM (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [1] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [1] Financial Results Announcement - Verona Pharma will report its financial results for the second quarter ended June 30, 2024, on August 8, 2024 [2] - An investment community conference call will be held at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update [2] Webcast Information - A live webcast will be available on the Events and Presentations link on the Investors page of the company's website [3] - An audio replay of the webcast will be available for 90 days [3]